BeiCell
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $14M
Investors
- 6
About BeiCell
, Ltd. doing business as BeiCell, operates as a bitechnology company that engages in the development of small molecule drug that provides off-the-shelf cell therapy products. The company specializes in the development of cell therapy drugs based on the chemically induced pluripotent stem cell (CiPSC) technology platform. This platform reprograms human somatic cells into pluripotent stem cells that exhibit key characteristics of embryonic stem cells, providing significant advantages over traditional methods, such as safety, simplicity, and efficiency. The primary service involves extracting immune cells from healthy donors utilizing various sources, including peripheral blood and cord blood, which are then engineered, expanded, and administered to patients as allogeneic or 'off-the-shelf' immunotherapy. Targeted end-use cases for these therapies include treatment options for various diseases, enhancing patient outcomes in immunotherapy. BeiCell's revenue structure is centered around B2B transactions, wherein the company collaborates with healthcare institutions and research organizations to provide advanced cell therapy solutions.
Who invested in BeiCell
6 investors across 2 rounds
See all investors in BeiCell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BeiCell
Who invested in BeiCell?
BeiCell has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BeiCell raised?
BeiCell has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BeiCell last raise money?
BeiCell's most recent round on record is a Series A, in Dec 2025.
What does BeiCell do?
BeiCell is a biotechnology company.
Where is BeiCell headquartered?
BeiCell is headquartered in Beijing, China.
Which VCs invest in companies like BeiCell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BeiCell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BeiCell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.